Program
Finasteride
Also written as “Finasteride 5 mg Tablet, single dose”, “minoxidil + finasteride” and “Finasteride 5 mg tablets”.
Its studies are mostly in Alopecia · Prostatic Hyperplasia · Acne Vulgaris, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. Reddy's Laboratories | 40 open or running | phase 1since May 27, 2010 | May 27, 2010 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Feb 3, 2009 | Feb 3, 2009 | none ahead |
| Il-Yang Pharm. | 21 open or running | phase 3since Oct 6, 2026 | Dec 11, 2025 | Aug 31, 2027phase 3 · NCT07870759 |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Almirall | 10 open or running | phase 1since Jun 1, 2016 | Jun 1, 2016 | none ahead |
| Beijing Dayspring Pharmaceutical Technology | 10 open or running | phase 2since Jul 1, 2025 | Jul 1, 2025 | none ahead |
| Elorac | 10 open or running | phase 2since Jul 10, 2015 | Jul 10, 2015 | none ahead |
| HairDx | 10 open or running | phase 1since Jan 16, 2010 | Jan 16, 2010 | none ahead |
| Merck | 10 open or running | phase 3since Feb 13, 2012 | Feb 13, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2008First studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00650377, NCT00648791
- Feb 3, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00835796, NCT00835666
- Mar 26, 20092 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT00871247, NCT00870480
- Jan 16, 2010HairDx's first study: phase 1 study in AlopeciaNew to HairDxHairDx · NCT01052870 · 12 enrolled
- May 27, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01133457, NCT01133444
- Dec 20, 20102 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01264302, NCT01264289
- Feb 13, 2012Merck's first study: phase 3 study in Prostatic HyperplasiaNew to MerckMerck · NCT01534351 · 1 enrolled
- Jul 10, 2015Elorac's first study: phase 2 study in Acne VulgarisNew to EloracElorac · NCT02502669 · 106 enrolled · United States
- Jun 1, 2016Almirall's first study: phase 1 study in AlopeciaNew to AlmirallAlmirall · NCT02791243 · 58 enrolled · United Kingdom
- Jul 1, 2025Beijing Dayspring Pharmaceutical Technology's first study: phase 2 study in AlopeciaNew to Beijing Dayspring Pharmaceutical TechnologyBeijing Dayspring Pharmaceutical Technology · NCT07076706 · 110 enrolled · China
- Dec 11, 2025Il-Yang Pharm.'s first study: phase 1 study in Healthy Adult MaleNew to Il-Yang Pharm.Il-Yang Pharm. · NCT07322991 · 43 enrolled · South Korea
- Oct 6, 2026Phase 3 study in Prostatic HyperplasiaPhase 3 reachedIl-Yang Pharm. · NCT07870759 · 660 planned
Ahead
- Aug 31, 2027Primary completion: phase 3 study in Prostatic HyperplasiaIl-Yang Pharm. · NCT07870759
TargetBeta
“Steroid 5-alpha-reductase 2 inhibitor”ChEMBL 37, by rule
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07870759Prostatic Hyperplasia | 3 | Not yet recruiting | Il-Yang Pharm. | Aug 31, 2027 | 660 |
| NCT07322991Healthy Adult Male · South Korea | 1 | Completed | Il-Yang Pharm. | Dec 1, 2025 | 43 |
| NCT07076706Alopecia · China | 2 | Completed | Beijing Dayspring Pharmaceutical Technology | Aug 26, 2025 | 110 |
| NCT02791243Alopecia · United Kingdom | 1 | Completed | Almirall | Jun 2016 | 58 |
| NCT02502669Acne Vulgaris · United States | 2 | Completed | Elorac | Jun 6, 2017 | 106 |
| NCT01534351Prostatic Hyperplasia | 3 | Terminated | Merck | Nov 18, 2013 | 1 |
| NCT01264302Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Nov 2006 | 26 |
| NCT01264289Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Nov 2006 | 26 |
| NCT01133457Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | May 2002 | 24 |
| NCT01133444Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Apr 2002 | 24 |
| NCT01052870Alopecia | 1 | Completed | HairDx | Dec 2009 | 12 |
| NCT00871247Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2004 | 26 |
| NCT00870480Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2004 | 26 |
| NCT00835796Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2002 | 20 |
| NCT00835666Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 2002 | 32 |
| NCT00650377Healthy · United States | 1 | Completed | Viatris | Oct 2004 | 30 |
| NCT00648791Healthy · United States | 1 | Completed | Viatris | Oct 2004 | 29 |
How it is read
Names in the registry
- “Finasteride”, 6 entries
- “Finasteride 5 mg Tablet, single dose”, 3 entries
- “minoxidil + finasteride”, 2 entries
- “Finasteride 5 mg tablets”, 2 entries
- “Finasteride Tablets 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Alopecia, 3 studies
- Prostatic Hyperplasia, 2 studies
- Acne Vulgaris, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.